CA3174699A1 - Ginsenoside compositions - Google Patents

Ginsenoside compositions

Info

Publication number
CA3174699A1
CA3174699A1 CA3174699A CA3174699A CA3174699A1 CA 3174699 A1 CA3174699 A1 CA 3174699A1 CA 3174699 A CA3174699 A CA 3174699A CA 3174699 A CA3174699 A CA 3174699A CA 3174699 A1 CA3174699 A1 CA 3174699A1
Authority
CA
Canada
Prior art keywords
ginsenosides
composition
increasing
gut microbiota
scfas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174699A
Other languages
English (en)
French (fr)
Inventor
Romain LECOZANNET
Pascale Elizabeth Renee Fanca-Berthon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Givaudan SA
Original Assignee
Givaudan SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004121.6A external-priority patent/GB202004121D0/en
Priority claimed from GBGB2005288.2A external-priority patent/GB202005288D0/en
Application filed by Givaudan SA filed Critical Givaudan SA
Publication of CA3174699A1 publication Critical patent/CA3174699A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CA3174699A 2020-03-20 2021-03-17 Ginsenoside compositions Pending CA3174699A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2004121.6A GB202004121D0 (en) 2020-03-20 2020-03-20 Improved compositions
GB2004121.6 2020-03-20
GBGB2005288.2A GB202005288D0 (en) 2020-04-09 2020-04-09 Improved compositions
GB2005288.2 2020-04-09
PCT/EP2021/056803 WO2021185897A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Publications (1)

Publication Number Publication Date
CA3174699A1 true CA3174699A1 (en) 2021-09-23

Family

ID=75108332

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3174699A Pending CA3174699A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions
CA3174698A Pending CA3174698A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3174698A Pending CA3174698A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Country Status (8)

Country Link
US (2) US20230124503A1 (https=)
EP (2) EP4121061A1 (https=)
JP (2) JP7850670B2 (https=)
CN (2) CN115315266A (https=)
AU (2) AU2021238639A1 (https=)
BR (2) BR112022015826A2 (https=)
CA (2) CA3174699A1 (https=)
WO (2) WO2021185890A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021185890A1 (en) * 2020-03-20 2021-09-23 Givaudan Sa Ginsenoside compositions
CN117224553B (zh) * 2023-11-02 2025-08-12 浙江大学 人参皂苷Rg3在制备治疗或预防肠道病毒感染的药物中的应用
CN117752706B (zh) * 2023-12-20 2025-10-14 浙江天皇药业有限公司 西洋参炮制品在制备治疗甲状腺功能减退症药物中的应用
WO2025261873A1 (en) 2024-06-20 2025-12-26 Givaudan Sa Improvements in or relating to compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202731A1 (en) * 2003-04-08 2004-10-14 Gow Robert T. Rosmarinic acid composition
US9956241B2 (en) * 2009-05-04 2018-05-01 Naturex, S.A. Application of American Ginseng to enhance neurocognitive function
US20100278944A1 (en) 2009-05-04 2010-11-04 Naturex, S.A. Application of american ginseng to enhance neurocognitive function
US10456436B2 (en) * 2013-11-04 2019-10-29 Wen Luan Wendy Hsiao Use of herbal saponins to regulate gut microflora
JP7223754B2 (ja) 2017-07-18 2023-02-16 セネッセンス ライフ サイエンセズ プライベート リミテッド 認知機能の低下の治療および予防、また神経機能の保持に関する組成物およびその方法。
CN110613802A (zh) 2018-06-20 2019-12-27 珠海岐微生物科技有限公司 白茅根大黄炭三七组合物及其在调节肠道微生物中的用途
CN109432304A (zh) * 2018-12-03 2019-03-08 杭州胡庆余堂药业有限公司 一种含铁皮石斛组合物在药物制备中的应用
WO2021185890A1 (en) 2020-03-20 2021-09-23 Givaudan Sa Ginsenoside compositions

Also Published As

Publication number Publication date
CA3174698A1 (en) 2021-09-23
US20230129389A1 (en) 2023-04-27
CN115315264A (zh) 2022-11-08
JP7808042B2 (ja) 2026-01-28
BR112022016241A2 (pt) 2022-10-11
US20230124503A1 (en) 2023-04-20
AU2021238639A1 (en) 2022-09-15
BR112022015826A2 (pt) 2022-10-04
EP4121061A1 (en) 2023-01-25
EP4121076A1 (en) 2023-01-25
WO2021185890A1 (en) 2021-09-23
AU2021238643A1 (en) 2022-10-20
JP2023518064A (ja) 2023-04-27
WO2021185897A1 (en) 2021-09-23
JP7850670B2 (ja) 2026-04-23
JP2023519189A (ja) 2023-05-10
CN115315266A (zh) 2022-11-08

Similar Documents

Publication Publication Date Title
US20230124503A1 (en) Ginsenoside compositions
Tian et al. Digestive characteristics of Hericium erinaceus polysaccharides and their positive effects on fecal microbiota of male and female volunteers during in vitro fermentation
Chung et al. Fermented milk of Lactobacillus helveticus IDCC3801 improves cognitive functioning during cognitive fatigue tests in healthy older adults
Martirosyan et al. The bioactive compounds of probiotic foods/supplements and their application in managing mental disorders
Liu et al. Microbiome and metabolome integrally reveal the anti-depression effects of Cistanche deserticola polysaccharides from the perspective of gut homeostasis
Chen et al. Ginsenoside Rb1 exerts neuroprotective effects through regulation of Lactobacillus helveticus abundance and GABAA receptor expression
Campaniello et al. A narrative review on the use of probiotics in several diseases. Evidence and perspectives
CN102242152B (zh) 腐植酸活性组分、其制备方法、应用及含其的药物组合物
JPWO2008155999A1 (ja) Ｇａｂａ作動性ニューロン賦活剤
CN110636760A (zh) 肠道健康促进组合物
Florina et al. The Interdependence between diet, microbiome, and human body health-a systemic review
Kuate et al. The use of Cissus quadrangularis (CQR-300) in the management of components of metabolic syndrome in overweight and obese participants
Li et al. Uncovering the effect of Moringa oleifera Lam. leaf addition to Fuzhuan Brick Tea on sensory properties, volatile profiles and anti-obesity activity
JP7514926B2 (ja) 個別化腸内細菌叢の多様性を整える機能を有する組成物及び使用
Lin et al. Komagataeibacter hansenii CGMCC 3917 alleviates alcohol-induced liver injury by regulating fatty acid metabolism and intestinal microbiota diversity in mice
WO2020049560A1 (en) Methods for supporting weight loss and weight loss maintenance by administration of aquatic plants and/or autologous microbiome samples
Yang et al. Effects of extracted oil of fermented Tartary buckwheat on lipid-lowering, inflammation modulation, and gut microbial regulation in mice
Yang et al. The regulatory effects of Lonicera japonica flos on fecal microbiota from humans with type 2 diabetes in a SHIME model
Li et al. Hemp seed oil ameliorates CFA-induced rheumatoid arthritis in rats by improving metabolic abnormalities and gut microflora
Tampanna et al. The role of kratom (Mitragyna speciosa Korth.) extract in medical foods for obese patients: Effects on gut microbiota in a colon model
Yang et al. The short-term and long-term effects of Dendrobium officinale leaves polysaccharides on the gut microbiota differ
TWI810645B (zh) 乳桿菌組合物及其改善抗生素造成之焦慮症的用途
Chi Study on biofate and antidepressive mechanism of fructooligosaccharides from Morinda officinalis
EP3370751B1 (en) Lentil extract with cholesterol lowering and prebiotic activity
WO2026078116A1 (en) Substances for use as a prebiotic or as a medicine

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250311

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250313

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250324

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250324

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250324

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250512

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260309

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260309

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260311